This issue of Biomedical Financing News focuses on 9 high-quality enterprises, covering core tracks in multiple fields: Panyun Medical promotes the domestic substitution and globalization of high-end suture consumables, Noah’s Source Medical deeply cultivates the import substitution of high-end flow cytometers, Weiyuan Synthesis breaks through the bottleneck of AI biological computing with the PoseX platform, the era of synthesis solves industrial enzyme pain points with “protein x material”, Xiran Medical and Tupai Medical focus on high-end ophthalmic equipment, Hongji Medical leads the way in disposable endoscopes going global, and various enterprises have obtained tens of millions to hundreds of millions of yuan in financing, accelerating technology landing and industrial upgrading.

---

1、 Panyun Medical has completed an angel round financing of nearly 100 million yuan, leading the domestic substitution and global layout of high-end suture consumables with technological innovation

Recently, Shanghai Bangyun Medical announced the completion of nearly 100 million yuan angel round financing, led by Daotong Investment, which is deeply involved in the field of life sciences, and followed by Jinding Capital. This round of financing will focus on expanding the production capacity of high-end absorbable sutures, tackling the independent supply chain of local raw materials, and developing and commercializing the world’s first BESURE self powered suture, strengthening the core competitiveness of domestic high-end wound closure consumables.

The current demand for surgical sutures in China is highlighted, with an estimated scale of 8.6 billion yuan by 2026. However, over 70% of the high-end market is monopolized by foreign investment, and core materials and technologies are subject to long-term control. Panyun Medical breaks through with technological innovation, its Weijia ® The absorbable knot free barbed wire is suitable for minimally invasive scenarios, and the unique triclosan antibacterial thread technology solves clinical pain points. The world’s first self generating suture developed jointly can accelerate wound healing by 50%. The results were published in Nature Communications, breaking the technical barrier of foreign investment.

Relying on a core team with backgrounds in multinational corporations such as Johnson&Johnson and Braun, the company has won the bid for centralized procurement in 24 provinces for all product categories and ranks among the top tier of the barbed wire. At the same time, with an international certified quality system, it has reached a million root level production capacity cooperation with Medtronic, achieving a breakthrough in both domestic and international markets. This round of financing is in line with the bottom layout opportunities of the medical and health track, which will help enterprises accelerate domestic substitution and global expansion, and promote the upgrading of the high-end wound suturing industry towards innovation driven development.

---

2、 Noah’s Source Medical has completed a nearly 100 million yuan angel round of financing and is deeply involved in the domestic replacement of high-end flow cytometers

In March 2026, Shanghai Noah’s Source Medical announced the completion of an angel round financing of nearly 100 million yuan, led by Hongsheng Capital, which focuses on investment in the medical and health field, and followed by Yiruixing Capital. This round of financing will focus on the industrialization of the core technology of full spectrum flow cytometry, accelerating the breakthrough of the monopoly pattern of high-end life science instrument imports.

Noah’s Source Medical focuses on the research and development of high-end wound closure consumables and full spectrum flow cytometers. With a completely independently developed technology platform, it breaks through industry pain points such as traditional flow cytometry technology channel limitations and fluorescence leakage. Its Lymacete series products cover the entire scene of single laser to multi laser, which can meet the needs of different levels of scientific research and clinical practice. It has achieved stable installation in top universities and research institutions in China.

The current high-end life science instruments are a key breakthrough in the “bottleneck” field of the country, and the import dependence of the flow cytometer market exceeds 95%. Relying on policy dividends and core technological advantages, Noah’s Source Medical leverages its independently developed spectral acquisition and analysis technology to build a differentiated product matrix and break the monopoly of foreign brands in the high-end field.

After this financing, the company will further promote core technology iteration and capacity upgrading, deepen cooperation with leading institutions, and leverage the industrial resources of investors to accelerate the clinical translation and global layout of full spectrum flow cytometers, helping domestic high-end scientific instruments achieve import substitution and create a national benchmark for high-end life science instruments.

---

3、 Weiyuan Synthesis has completed a 300 million yuan A+round financing, breaking through the core bottleneck of AI bio computing with the PoseX platform

Recently, Beijing MicroCyto officially announced the completion of a 300 million yuan A+round financing, jointly invested by Henan Investment Group Huirong Fund and Mr. Tan Ruiqing. Among them, Henan Investment Group has completed the full chain layout of AI infrastructure, which can provide sufficient computing power and power support; Mr. Tan Ruiqing has been deeply involved in the chemical industry for over 30 years, possessing both industrial resources and industry insights. This round of financing will focus on PoseX AI biocomputing platform iteration, core algorithm research and development, and industrial scenario implementation, consolidating the company’s technological barriers in AI enabled biomanufacturing.

As a breakthrough in core technology, Microelement Synthesis, together with Stanford University, Princeton University, ByteDance and other institutions, released the open AI biological computing platform PoseX in ICLR 2026, specifically tackling the industry’s core problem of molecular docking “cross conformation”, and filling the gap in the evaluation benchmark of molecular docking in the global real scene. The platform has built a cross conformational docking dataset with 1312 sample points and a self docking dataset with 718 sample points, integrating 24 mainstream algorithms. After rigorous testing and verification, the accuracy of top AI docking methods is 20 percentage points ahead of traditional physical models.

The core advantage of PoseX lies in its innovative Relaxation post-processing module, which can repair molecular structure collision problems and achieve a success rate of 77% for the SurfDock algorithm in cross conformational docking, setting an industry SOTA. Based on this platform, microbial synthesis can achieve efficient enzyme evolution and metabolic pathway optimization, compressing the traditional wet experiment research and development cycle from months to weeks, significantly reducing the cost and risk of biomanufacturing research and development. At present, this technology has gradually been transformed into industrial competitiveness, supporting the development of high-value biobased products and “super catalysts”.

This financing will promote the deepening of open source collaboration on the PoseX platform, accelerate the landing of technology in biological manufacturing, new drug research and development, and other scenarios. At the same time, with the help of investor resources, it will strengthen the industrial transformation ability of AI bio computing technology, assist micro element synthesis in building a global leading AI+synthetic biology innovation benchmark, and promote the industry’s transformation from traditional experimental driven to AI native research and development mode.

---

4、 Synthetic Era has completed tens of millions of yuan in Pre-A round financing, breaking through the bottleneck of industrial enzyme applications with “protein x material”

Shenzhen Synthetic Era announced the completion of tens of millions of yuan in Pre-A round financing, led by Huaxi Yuanyou, followed by Yigao Capital, and with Xiqiao Capital serving as the exclusive financial advisor. This round of funds will be used for the core platform CatalEditor ® Iteration, new product development, market expansion, and team expansion accelerate the industrialization of “protein x material” technology.

The company focuses on industrial enzyme preparations and biocatalysts, relying on the “protein carrier materials” database of the Tsinghua team for nearly 20 years, to create the international first CatalEditor ® Protein AI design and material packaging platform, constructing AI4M research and development paradigm. Founder Professor Ge Jun is a global pioneer in the industrialization of enzyme MOF encapsulation technology, using MOFs in situ encapsulation to construct a “molecular armor” for proteins, overcoming the industry pain points of protein inactivation under harsh environments such as high temperature and acidity.

The platform adopts AI driven “sequence structure function” iteration, combined with self-developed PHBO algorithm, greatly reducing the research and development cycle. The relevant results have been published in the top issue of the Nature series. At present, the entire production chain from the laboratory to the hundred ton level has been connected, and commercialization has been achieved in the fields of carbon capture, healthy consumption, textile antibacterial, etc., forming a closed loop with multiple leading brands.

The investors stated that the company, with its original technology and full chain engineering capabilities, has become a scarce MOF Nobel Prize technology industrialization platform in China, with broad alternative space in fields such as green manufacturing and new energy. This round of financing will help the company deepen its technological barriers and promote the large-scale implementation of synthetic biomanufacturing.

---

5、 Xiran Medical has completed a Series B financing of nearly 100 million yuan to accelerate the import substitution of the first domestically produced super milk glass cutting machine

Zhejiang Xiran Medical recently announced the completion of a Series B financing of nearly 100 million yuan, led by Yuexiu Industrial Fund and co invested by Taiyu Investment. This round of funds will mainly be used for the domestic and international market promotion of the first domestically approved super milk glass cutting all-in-one machine, the registration and launch of a new generation product, and clinical trials, further consolidating the company’s technical barriers in the field of high-end ophthalmic surgical equipment and accelerating the process of import substitution of domestically produced high-end ophthalmic equipment.

Founded in 2021, Xiran Medical focuses on independent research and development of high-end ophthalmic surgical equipment, and builds a full chain solution of “equipment+consumables+training”. Its core product is the XR Genesis super milk glass cutting machine ® For the first domestically approved device of its kind, breaking the long-standing monopoly of overseas brands in one fell swoop. This device can achieve a one-time surgical combination treatment for cataract combined with fundus disease, significantly reducing surgical trauma and having significant clinical advantages compared to traditional split type devices.

Currently, the size of China’s ophthalmic medical market has exceeded 250 billion yuan, and the ophthalmic equipment market is expected to reach 93.3 billion yuan by 2030, but the high-end field has long been dominated by foreign investment. The institutional side unanimously believes in its development prospects: Yuexiu Industrial Fund recognizes its innovative ability in medical engineering integration, which will help accelerate domestic substitution; Taiyu Investment pointed out that its product performance is leading, in line with the habits of domestic doctors, and is expected to break foreign monopolies. This round of financing will accelerate the technological iteration and global layout of Xiran Medical, enhance the accessibility of high-end ophthalmic equipment with inclusive technology, and help upgrade China’s ophthalmic medical equipment industry.

---

6、 Hongji Medical has completed a financing of billions of yuan, leading the global market for disposable endoscopes

Shenzhen Hongji Medical recently completed a billion yuan financing, led by Fengnian Capital and Qiming Venture Capital, with Xiamen Jianfa, Sunshine Insurance, and Xiaodan Venture Capital as co investors. This round of funding will focus on core technology iteration, global channel expansion, and capacity upgrading, further consolidating the company’s leading position in the field of disposable endoscopes and accelerating the global penetration of domestically produced high-end endoscopic instruments.

Established in 2014, Hongji Medical is deeply engaged in the research and development, production, and sales of disposable endoscopes. It is a national high-tech enterprise and a specialized and innovative “little giant” enterprise, with a total of 110+invention patents and the ability to independently research and develop the entire chain from optical components to precision structural components. Its core technical indicators are comparable to the international first-class level. The 6.3Fr ureteroscope launched by it is the world’s first ultra-fine product of this specification, breaking through the bottleneck of minimally invasive diagnosis and treatment technology. The product pipeline covers 6 major clinical scenarios and has a large-scale production capacity of 400000 pieces per year. It is the most comprehensive disposable endoscope manufacturer in China.

The core competitiveness of the company lies in its high barrier globalization certification and channel layout. As the first Chinese enterprise in the world to obtain the CE MDR certification for disposable endoscopes, it has obtained 103 major global market certifications such as NMPA, CE, FDA, etc. Its products are sold well in more than 100 countries and regions, building a global closed loop of “certification product channel brand” and breaking the monopoly pattern of foreign investment in the high-end field.

The current disposable endoscope market is growing rapidly, and the Chinese market is expected to reach 9.4 billion yuan by 2030, with vast opportunities for domestic substitution and overseas expansion. The investor, Fengnian Capital, stated that it will leverage its industrial resource advantages to assist Hongji Medical in strengthening technological innovation and global layout; Qiming Venture Capital recognizes its full chain industrialization capability and overseas potential. This round of financing will accelerate the company’s product iteration and deep cultivation in overseas markets, creating a benchmark for domestic high-end endoscopes going global.

---

7、 Tupai Medical has completed a 400 million yuan Pre IPO round of financing, targeting the first stock of ophthalmic equipment on the Science and Technology Innovation Board

Tupai Medical (Beijing) recently completed its share reform and 400 million yuan Pre IPO round of financing. This round is led by Chengdu Sci Tech Innovation Investment Group, with Beijing Pharmaceutical and Health Industry Fund, Sichuan Sci Tech Innovation Investment Group and other old shareholders continuing to increase their investments. The funds will be mainly used for IPO preparation, improvement of the product matrix across all categories, and deepening of global layout, striving to become the first stock of ophthalmic equipment on the Science and Technology Innovation Board.

As a leading enterprise in high-end ophthalmic medical equipment in China, Tupai Medical adheres to independent and controllable control of the entire industry chain, and its core technology has reached the international leading level. It is the world’s first intraoperative scanning OCT navigation technology, applied to ophthalmic surgical microscopes, breaking decades of foreign monopoly in the high-end surgical microscope field. The “Biyun” model costs nearly 6 million yuan per unit, setting a record for the price of domestic ophthalmic equipment. Within six months of its listing, the terminal bid amount was nearly 100 million yuan.

The company’s core product advantages are significant: the ultra high speed scanning OCT technology has won the Beijing Science and Technology Progress Award, with a cumulative installed capacity of over 1200 units at home and abroad, and a stable market share in the European Union; AI fundus assisted diagnostic products have entered the special review channel for innovative medical devices, and multiple categories of products under research are steadily advancing. At the same time, the company has established an industry university research integration system, laid out cross departmental products, and formed a complete technology transformation chain.

The investors highly recognize its technological barriers and commercialization capabilities. This round of financing will further strengthen core technology research and development, accelerate product iteration and overseas market penetration, consolidate its leading position in the industry, and help it become a benchmark enterprise for the industrialization and globalization of domestic high-end ophthalmic medical equipment.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.